Setback for Genentech

Article

The FDA has denied Genentech's request to fast-track the application for its age-related macular degeneration (AMD) agent, Lucentis (ranibizumab). In response, Genentech announced it plans to file a complete Biologics License Application (BLA) for Lucentis for the treatment of neovascular AMD in December 2005, in a bid to speed up the process. Although the FDA rejected Genentech's request for fast-track designation, this should not affect the timing for BLA submission or the potential to obtain priority review.

Related Videos
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Dr Ali Erginay discusses his EURETINA presentation
© 2023 MJH Life Sciences

All rights reserved.